OBJECTIVE: A recent study provisionally identified numerous genetic variants as risk factors for the transition from smoking to the development of nicotine dependence, including an amino acid change in the alpha5 nicotinic cholinergic receptor (CHRNA5). The purpose of this study was to replicate these findings in an independent data set and more thoroughly investigate the role of genetic variation in the cluster of physically linked nicotinic receptors, CHRNA5-CHRNA3-CHRNB4, and the risk of smoking. METHOD: Individuals from 219 European American families (N=2,284) were genotyped across this gene cluster to test the genetic association with smoking. The frequency of the amino acid variant (rs16969968) was studied in 995 individuals from diverse ethnic populations. In vitro studies were performed to directly test whether the amino acid variant in the CHRNA5 influences receptor function. RESULTS: A genetic variant marking an amino acid change showed association with the smoking phenotype (p=0.007). This variant is within a highly conserved region across nonhuman species, but its frequency varied across human populations (0% in African populations to 37% in European populations). Furthermore, functional studies demonstrated that the risk allele decreased response to a nicotine agonist. A second independent finding was seen at rs578776 (p=0.003), and the functional significance of this association remains unknown. CONCLUSIONS: This study confirms that at least two independent variants in this nicotinic receptor gene cluster contribute to the development of habitual smoking in some populations, and it underscores the importance of multiple genetic variants contributing to the development of common diseases in various populations.
OBJECTIVE: A recent study provisionally identified numerous genetic variants as risk factors for the transition from smoking to the development of nicotine dependence, including an amino acid change in the alpha5 nicotinic cholinergic receptor (CHRNA5). The purpose of this study was to replicate these findings in an independent data set and more thoroughly investigate the role of genetic variation in the cluster of physically linked nicotinic receptors, CHRNA5-CHRNA3-CHRNB4, and the risk of smoking. METHOD: Individuals from 219 European American families (N=2,284) were genotyped across this gene cluster to test the genetic association with smoking. The frequency of the amino acid variant (rs16969968) was studied in 995 individuals from diverse ethnic populations. In vitro studies were performed to directly test whether the amino acid variant in the CHRNA5 influences receptor function. RESULTS: A genetic variant marking an amino acid change showed association with the smoking phenotype (p=0.007). This variant is within a highly conserved region across nonhuman species, but its frequency varied across human populations (0% in African populations to 37% in European populations). Furthermore, functional studies demonstrated that the risk allele decreased response to a nicotine agonist. A second independent finding was seen at rs578776 (p=0.003), and the functional significance of this association remains unknown. CONCLUSIONS: This study confirms that at least two independent variants in this nicotinic receptor gene cluster contribute to the development of habitual smoking in some populations, and it underscores the importance of multiple genetic variants contributing to the development of common diseases in various populations.
Authors: Howard M Cann; Claudia de Toma; Lucien Cazes; Marie-Fernande Legrand; Valerie Morel; Laurence Piouffre; Julia Bodmer; Walter F Bodmer; Batsheva Bonne-Tamir; Anne Cambon-Thomsen; Zhu Chen; J Chu; Carlo Carcassi; Licinio Contu; Ruofu Du; Laurent Excoffier; G B Ferrara; Jonathan S Friedlaender; Helena Groot; David Gurwitz; Trefor Jenkins; Rene J Herrera; Xiaoyi Huang; Judith Kidd; Kenneth K Kidd; Andre Langaney; Alice A Lin; S Qasim Mehdi; Peter Parham; Alberto Piazza; Maria Pia Pistillo; Yaping Qian; Qunfang Shu; Jiujin Xu; S Zhu; James L Weber; Henry T Greely; Marcus W Feldman; Gilles Thomas; Jean Dausset; L Luca Cavalli-Sforza Journal: Science Date: 2002-04-12 Impact factor: 47.728
Authors: Laura Jean Bierut; John P Rice; Alison Goate; Anthony L Hinrichs; Nancy L Saccone; Tatiana Foroud; Howard J Edenberg; C Robert Cloninger; Henri Begleiter; P Michael Conneally; Raymond R Crowe; Victor Hesselbrock; Ting-Kai Li; John I Nurnberger; Bernice Porjesz; Marc A Schuckit; Theodore Reich Journal: Am J Med Genet A Date: 2004-01-01 Impact factor: 2.802
Authors: Noah A Rosenberg; Jonathan K Pritchard; James L Weber; Howard M Cann; Kenneth K Kidd; Lev A Zhivotovsky; Marcus W Feldman Journal: Science Date: 2002-12-20 Impact factor: 47.728
Authors: T Foroud; H J Edenberg; A Goate; J Rice; L Flury; D L Koller; L J Bierut; P M Conneally; J I Nurnberger; K K Bucholz; T K Li; V Hesselbrock; R Crowe; M Schuckit; B Porjesz; H Begleiter; T Reich Journal: Alcohol Clin Exp Res Date: 2000-07 Impact factor: 3.455
Authors: Michael K Tian; Craig D C Bailey; Mariella De Biasi; Marina R Picciotto; Evelyn K Lambe Journal: J Neurosci Date: 2011-11-09 Impact factor: 6.167
Authors: Gabe Haller; Todd Druley; Francesco L Vallania; Robi D Mitra; Ping Li; Gustav Akk; Joe Henry Steinbach; Naomi Breslau; Eric Johnson; Dorothy Hatsukami; Jerry Stitzel; Laura J Bierut; Alison M Goate Journal: Hum Mol Genet Date: 2011-10-31 Impact factor: 6.150
Authors: Tyler J VanderWeele; Kofi Asomaning; Eric J Tchetgen Tchetgen; Younghun Han; Margaret R Spitz; Sanjay Shete; Xifeng Wu; Valerie Gaborieau; Ying Wang; John McLaughlin; Rayjean J Hung; Paul Brennan; Christopher I Amos; David C Christiani; Xihong Lin Journal: Am J Epidemiol Date: 2012-02-03 Impact factor: 4.897
Authors: Lawrence Toll; Nurulain T Zaveri; Willma E Polgar; Faming Jiang; Taline V Khroyan; Wei Zhou; Xinmin Simon Xie; Gregory B Stauber; Matthew R Costello; Frances M Leslie Journal: Neuropsychopharmacology Date: 2012-01-25 Impact factor: 7.853